|
Title
|
Status
|
|
|
Recruiting
in 1 of 1 locations
|
|
Breast Cancer is the most commonly diagnosed cancer in women in North America. Despite effective therapies, many women develop metastatic disease (ie disease that has spread outside of the breast to other parts of the body). For these women, the goal of care is to improve quality of life and, where possible, prolong quantity of life. The most common site of metastatic disease is spread to the bone. Bone metastases can significantly affect patients quality of life by causing pain, fractures, spinal cord compression, and life-threatening biochemical abnormalities (high calcium in the blood). Bisphosphonate drugs are medications that have been proven to decrease the frequency of these events. At present, however, the best way to deliver these drugs is not known. We aim to develop a risk score for women with bone metastases, so that we can stratify women into low, medium, and high risk categories. This will allow us to tailor treatment for bone metastases based on risk category.
|
|
|
Recruiting
in 0 of 3 locations
|
|
The study will investigate the comparative efficacy and safety of two oral inhibitors of Kit and PDGFR: nilotinib 400 mg bid, a novel agent, and imatinib 400 mg bid, an approved agent with an established efficacy.
|
|
|
Recruiting
in 1 of 2 locations
|
|
The purpose of this study is to determine whether gonadotropin releasing hormone agonists (medical therapy) will protect against ovarian failure in reproductive aged women undergoing sterilizing chemotherapy.
|
|
|
Recruiting
in 1 of 1 locations
|
|
Nodal staging is a key-step in pre-treatment assessment of gynecological cancers. In recent years, lymphatic mapping and sentinel lymphadenectomy (LM/SL) as a minimally invasive pelvic lymph nodes staging has been successfully evaluated in women with early stage of vulvar cancer, cervical cancer, and endometrial cancer. Such a technique may offer several valuable advantages: a) it is readily applicable in clinical routine using a safe, inexpensive, and reproducible protocol; b) it may help to avoid the cost and the morbidity of unnecessary lymphadenectomy in the majority of cases with uninvolved sentinel lymph nodes; c) it has the potential to guide the surgeon to nodal regions that are not routinely dissected (i.e. pre-sacral, para-aortic nodes) and to identify micro-metastases that would have been ignored otherwise; d) it also offers the basis for sophisticated pathological analysis to detect sub-microscopic nodal metastases using either immunohistochemical or molecular biological techniques. So far, within the abdomen and the pelvis, the LM/SL technique alone is often blinded to the accurate localization of SLNs. The integration of computed tomography (CT) to SPECT devices in a single gantry (SPECT/CT) has allowed a significant gain in terms of diagnostic accuracy and anatomic precision; clinical examples include malignant melanoma, head and neck cancer, breast cancer, and bladder cancer. In a seminal series of 26 patients with cervical cancer (Zhang et al., 2006), SPECT/CT was recently found superior to conventional planar imaging for detection of SLN and accurate localization. A more recent study (Kushner al., 2007) has also highlighted the technical feasibility and the clinical added-value of a low-dose SPECT/CT in a series of 20 patients with early stage cervical cancer (IA2-IIA) who underwent LM/SL. In the light of the encouraging data from literature and our own preliminary clinical experience, we hypothesized that the use of LM/SL plus SPECT/CT may be of clinical interest in patients with gynecological cancers.
|
|
|
Recruiting
in 2 of 2 locations
|
|
This is a double-blind, randomized, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of metastatic (stage IV) or advanced stage IIIB with malignant pleural effusion NSCLC. Approximately 3000 subjects with metastatic (stage IV) or advanced stage IIIB with malignant pleural effusion NSCLC receiving or about to receive first line chemotherapy will be enrolled into the study. Subjects will be randomized in a 2:1 allocation (Group A: darbepoetin alfa 500 µg Q3W, Group B: placebo Q3W)
|
|
|
Recruiting
in 4 of 4 locations
|
Stereotactic radiation therapy can send x-rays directly to the tumour and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumour cells. It is not yet known whether stereotactic radiation therapy is more effective with or without whole-brain radiation therapy in treating patients with brain metastases.
This randomized phase III trial is studying stereotactic radiation therapy and whole-brain radiation therapy to see how well they work compared with stereotactic radiation therapy alone in treating patients with brain metastases.
|
|
|
Recruiting
in 1 of 1 locations
|
|
Hepatocellular carcinoma (HCC) is one of the most common causes of global cancer death, with an increasing incidence in North America. Most patients are not suitable for surgery. Ablative therapies are an alternative treatment for some, but most patients have tumours too large for this. Stereotactic body radiation therapy (SBRT) refers to radiation therapy delivered precisely with a high dose volume conforming closely to the tumour, usually in less than 10 treatment fractions.
|
|
|
Recruiting
in 22 of 23 locations
|
|
To determine if Accelerated Partial Breast Irradiation, using 3D CRT, is as effective as
Whole Breast Irradiation following breast conserving surgery in women with an new
histological diagnosis of ductal carcinoma in situ only or invasive breast cancer without
evidence of metastatic disease. Effectiveness will be determined by the rate of ipsilateral
breast tumour recurrence.
General objective is to improve the convenience and quality of life of female patients who
receive breast irradiation.
|
|
|
Recruiting
in 1 of 1 locations
|
|
A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumour activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with advanced or metastatic solid tumours. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with paclitaxel and carboplatin for Phase 2 studies.
|
|
|
Recruiting
in 1 of 1 locations
|
|
The project outline which follows is a pilot investigation aimed at improving MRI parameters
in DCE-MRI to optimize the detection of treatment responses in LABC.
The primary objective is to define the activity of neoadjuvant chemotherapy in patients with
biopsy proven operable breast cancer. Secondary objectives include evaluating a new MRI
pulse sequence to optimize DCE-MRI of LABC responses.
|
